Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NiKang Therapeutics

Request full access

Privately-held biotech company focused on developing novel small molecule oncology drug discovery

Greenville, United StatesFounded 2017Biotech & Life Sciences

About NiKang Therapeutics

NiKang Therapeutics is an early-stage biotech startup that operates in the oncology sector. The company's primary focus is on the discovery and development of innovative small molecule medicines to treat cancer. These medicines are designed to meet the needs of patients for whom current treatments are insufficient or ineffective.

The company's approach to drug discovery is driven by an in-depth understanding of disease biology and molecular pathways. This means they study the biological processes and mechanisms involved in the development of cancer to identify potential targets for their drugs. Their drug design is informed by the structure of these targets, allowing them to create drugs that can effectively interact with and influence these biological processes.

NiKang's business model is centered around the rapid and efficient discovery and advancement of proprietary drug candidates. These candidates are selected based on their pharmacological features, with the most promising ones being moved into clinical studies. The company's ultimate goal is to bring transformative medicines to patients in need, thereby creating a revenue stream through the sale of these innovative treatments.

In summary, NiKang Therapeutics is a biotech startup operating in the oncology sector, focused on the discovery and development of innovative small molecule medicines to meet unmet patient needs. Their approach is driven by deep insights into disease biology and molecular pathways, and they aim to rapidly and efficiently advance promising drug candidates into clinical studies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
38
Open positions
None listed
Dealroom signal
70.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing May 2021 $200M $382M BlackRock · Matrix Partners China · Invus · Lilly Asia Ventures —
SERIES BOther financing Sep 2020 $50M $200M Matrix Partners China · Lilly Asia Ventures · Casdin Capital · RTW Investments ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

NiKang Therapeutics website traffic

Latest recorded traffic for NiKang Therapeutics is 1.8K monthly website visits, up 127.8% over the last three months. NiKang Therapeutics's team declined 9.5% over the past year.

Latest monthly visits1.8K 3-month web change+127.8% 1-year team growth-9.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

NiKang Therapeutics in the Greenville ecosystem

Live from Dealroom

The NiKang Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

22 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • CBC Group

Series A5 investors entered at this stage

Series B and later16 investors entered at this stage

Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NiKang Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NiKang Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.